MktsMarkets

Lyell Immunopharma, Inc.
NASDAQ: LYELKey statistics
LYEL News
Stories mentioning LYEL from around the web — every one is an open thread, so give it a like or add your take.
Loading news…
Financial statements
As filed, straight from the 10-Q — up to 19 years of history, free, with every line item chartable.
| Line item | Q1 '26Mar 31 | Q4 '25Dec 31 | Q3 '25Sep 30 | Q2 '25Jun 30 | Q1 '25Mar 31 | Q4 '24Dec 31 | Q3 '24Sep 30 | Q2 '24Jun 30 |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 2.00 | 6.00 | 15.00 | 8.00 | 7.00 | 11.00 | 34.00 | 13.00 |
| Cost of Goods Sold | ||||||||
| Gross Profit | ||||||||
| Operating Expenses | ||||||||
| Research & Development | 36,604 | 28,172 | 34,857 | 43,447 | 39,500 | 40,261 | ||
| Sales General & Admin | ||||||||
| Total Operating Expenses | 44,263 | 127,650 | 37,268 | 47,148 | 57,374 | 201,158 | 50,539 | 51,541 |
| Operating Income (Loss) | (44,261) | (127,644) | (37,253) | (47,140) | (57,367) | (201,147) | (50,505) | (51,528) |
| Interest Income | ||||||||
| Interest Expense | ||||||||
| Other Expense | 17,914 | (15,755) | (4,859) | 1,180 | 1,310 | 4,292 | (43.00) | (645.00) |
| Pretax Income | ||||||||
| Tax Provision | ||||||||
| Net Income (Loss) | (24,153) | (140,723) | (38,846) | (42,684) | (52,195) | (191,935) | (44,583) | (45,809) |
| Earnings Per Share (Basic) | (1.10) | (8.23) | (2.13) | (2.89) | (3.54) | (14.68) | (3.48) | (3.59) |
| Earnings Per Share (Diluted) | (1.10) | (8.23) | (2.13) | (2.89) | (3.54) | (14.68) | (3.48) | (3.59) |
| Weighted Average Shares Outstanding (Basic) | 21,876 | 17,093 | 18,268 | 14,793 | 14,755 | 13,074 | 12,815 | 12,770 |
| Weighted Average Shares Outstanding (Diluted) | 21,876 | 17,093 | 18,268 | 14,793 | 14,755 | 13,074 | 12,815 | 12,770 |
Scroll the table sideways for older periods — the line-item column and the period header stay put. Hover a row and use the chart handle to plot it over the full history.
About LYEL
Lyell Immunopharma, Inc. (NASDAQ: LYEL) is a stock listed on the Nasdaq Stock Market under the ticker symbol LYEL. It last traded at $13.67 (Nov 17, 2026, 4:00 PM ET), down 6.7% on the day. That gives Lyell Immunopharma a market capitalisation of $336.1M.
Over the past 52 weeks LYEL has traded between $7.20 and $45.00.
Revenue for the quarter ended Mar 31, 2026 was $2.0K; a net loss of $24.2M. Revenue was down 71.4% from $7.0K in the quarter ended Mar 31, 2025.
| Quarter ended | Revenue | Net income | Margin |
|---|---|---|---|
| Mar 31, 2026 | $2.0K | -$24.2M | -1207650.0% |
| Dec 31, 2025 | $6.0K | -$140.7M | -2345383.3% |
| Sep 30, 2025 | $15.0K | -$38.8M | -258973.3% |
| Jun 30, 2025 | $8.0K | -$42.7M | -533550.0% |
From Lyell Immunopharma’s quarterly (10-Q) filings, in US dollars.
Take a break — play a market game
Seven free games built around the markets. No download, no sign-up: they run right here in your browser.
Latest News
Market news from around the web — every story is an open thread, so give it a like or add your take.
Loading news…